Physician profile
Marc Lieberman
NPI 1528159092
$15,624.33
in general payments reported to CMS, 2019-2025
21 companies · $2,426 in 2025
The $2,426 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,224 · 2020: $1,745 · 2021: $1,802 · 2022: $2,623 · 2023: $2,319 · 2024: $2,485 · 2025: $2,426.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,138 · Education: $91.77.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,138.34 |
| Education | $91.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $3,825.45 | 2019-2025 | Enbrel, Otezla, Otezla |
| Abbvie INC. | $3,686.61 | 2019-2025 | |
| Janssen Biotech, INC. | $1,583.43 | 2019-2024 | Tremfya, Simponi, Simponi Aria |
| Pfizer INC. | $1,572.46 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $1,308.52 | 2019-2025 | |
| Glaxosmithkline, LLC. | $1,220.27 | 2019-2025 | Benlysta, Nucala |
| Janssen Scientific Affairs, LLC | $887.48 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $825.12 | 2021-2025 | Saphnelo |
| Ucb, INC. | $131.58 | 2023-2025 | Cimzia, Bimzelx |
| Mallinckrodt Enterprises LLC | $84.22 | 2019 | |
| Mallinckrodt Hospital Products INC. | $65.98 | 2020 | |
| Ani Pharmaceuticals, INC. | $61.09 | 2023-2025 | Purified Cortrophin Gel |
| Genzyme Corporation | $60.45 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $59.95 | 2020-2021 | |
| Lilly USA, LLC | $48.54 | 2020-2025 | Taltz |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $43.57 | 2020-2023 | Ofev |
| Hospira, INC. | $41.52 | 2024-2025 | |
| Octapharma USA, INC. | $40.67 | 2025 | Octagam Immune Globulin (Human) |
| Radius Health, INC. | $40.17 | 2019-2021 | |
| Scilex Pharmaceuticals INC. | $23.79 | 2025 | |
| Merck Sharp & Dohme LLC | $13.46 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marc Lieberman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.